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Abstract: Induction chemotherapy is often the first therapeutic intervention for acute myeloid leukemia (AML). Evalu-
ation of post induction bone marrow provides critical information for clinical management; in general increased 
blast counts or increased marrow cellularity is an ominous sign, suggestive of ineffective therapy, and may warrant 
additional rounds of chemotherapy. However, increased blasts alone are not necessarily predictive of recurrent/per-
sistent disease. Here we report a very unusual observation in a case of AML with a core binding factor beta (CBFB) 
rearrangement. In this case the day 21 post-induction marrow biopsy showed a high blast count (approximately 
20%), however, subsequent fluorescence in-situ hybridization studies were negative for CBFB rearrangement. We 
compared this finding to post-induction marrows from a series of 6 AML cases with CBFB rearrangements, none 
of which showed an increased blast count. This case illustrates that increased blast counts, even those compris-
ing 20% of cells, are not de facto evidence of induction failure, and that correlation with ancillary studies such as 
fluorescence in-situ hybridization should be used to distinguish a persistent neoplastic clone, from a brisk marrow 
recovery.
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Introduction 
Acute myeloid leukemia (AML) is a hematologic 
malignancy resulting from clonal expansion of 
myeloid precursors that involves peripheral 
blood, bone marrow, as well as extramedullary 
tissues. AML is the most common acute leuke-
mia in adults and was estimated to cause over 
10,000 deaths in 2012 [1]. According to cur-
rent 2008 WHO classification, a diagnosis of 
AML can be made when blasts exceed 20% in 
either peripheral blood or bone marrow. 
The initial treatment of nearly all subtypes of 
AML is induction chemotherapy. The actual reg-
imens are based on patients’ age, performance 
status and prior history of myelodysplasia or 
cytotoxic therapy. The purpose of induction is 
to reduce of tumor burden and restore normal 
hematopoiesis of the bone marrow. Post-
induction bone marrow evaluation is recom-
mended 7 to 10 days after induction, or com-
monly known as “Day 14 bone marrow” or less 
commonly “Day 21 bone marrow”, depending 
on various induction regimens. Important clini-
cal decisions are based on the findings from 
post-induction bone marrow, and patients who 
do not show an appropriate reduction in bone 
marrow blasts or bone marrow cellularity are 
often given additional rounds of induction 
chemotherapy.
Inversion 16, or t(16;16) involves the Core 
Binding Factor Beta (CBFB) gene and is consid-
ered as a favorable translocation with good out-
come of induction chemotherapy [2]. Here we 
report an unusual observation of a high per-
centage of non-neoplastic myeloblasts (approx-
imately 20% of total marrow cells) in a post-
induction bone marrow from an AML case with 
CBFB rearrangement. 
Case report
The patient was a 56 year-old woman with a 
past medical history of hypothyroidism and dia-
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Figure 1. Increased blasts in the aspirate and core biopsy of the Day 21 bone marrow. A, B. The Wright-Giemsa 
stained marrow aspirate contains increased number of immature precursors, characterized by slightly irregular 
nuclear contours, fine chromatin, prominent nucleoli, and moderate amounts of light basophilic cytoplasm. (Original 
magnification 1000x). C, D. Hematoxylin-Eosin stained core biopsy shows pockets of immature precursors with very 
little maturation of granulocytic lineage (Original magnification 600x).
betes mellitus presented to an outside hospital 
with progressive fatigue. Laboratory tests 
showed severe pancytopenia, including a 
hemoglobin level of 4 g/dL. A bone marrow 
aspirate was obtained, which showed “acute 
leukemia”. 
The patient was transferred to our institution 
and her CBC showed the following: WBCs 2.5 x 
109/L, RBCs 3.08 x 1012/L, Hemoglobin 10.3 
g/dL, Mean corpuscular volume (MCV) 96.4 fL, 
Platelets 43 x 109/L. An in-house bone marrow 
biopsy showed 12% blasts and eosinophils with 
abnormal granulations. Flow cytometry showed 
that 31% of analyzed events were CD34-
positive blasts with co-expression of CD13, 
CD117, CD33, HLA-DR, and negative for CD14, 
CD56, CD64, CD2, or CD5. The full cytogenetic 
karyotype was: 46XX,t(11;20)(p15;q11.2),inv 
(16)(p13.1q22)[9]/47,idem,+8[7]/46XX[4] and 
Fluorescent In Situ Hybridization (FISH) per-
formed on metaphase cells confirmed pres-
ence of CBFB rearrangement and trisomy 8. 
These findings were diagnostic of a AML with 
inv(16)/CBFB rearrangements, and the patient 
was enrolled in CALGB 10801, a phase II clini-
cal trial, and received 7+3 induction plus 13 
doses of dasatinib. 
A post-induction bone marrow biopsy was per-
formed at Day 21. Concurrent CBC was as fol-
lows: WBCs 0.7 x 109/L, RBCs 2.41 x 1012/L, 
Hemoglobin 7.7 g/dL, Hematocrit 21.5%, MCV 
89.3 fL, Red cell distribution width (RDW-CV) 
13.9%, Platelets 19 x 109/L. Review of periph-
eral blood showed pancytopenia with rare cir-
culating blasts. The marrow aspirate and core 
biopsy revealed a hypocellular specimen with 
19% blasts by manual differential count (Figure 
1). The blasts were characterized by fine chro-
matin, large nucleoli, and moderate amount of 
light basophilic cytoplasm. Flow cytometric 
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Table 1. Blast Counts of Day 21 Marrows of AML with 
CBFB rearrangements
No Age/Sex D21 Blast% D21 FISH F/U FISH (interval)
1$ 56/F 21 Negative Negative
2 62/F 2 0.33% Negative (+12 days)
3 24/F 2 N/A Negative
4 71/F 1 Negative Negative
5 55/M 4 Negative Negative
6 48/M 2 N/A Negative
7* 29/M 0 1.50% 0.30% (+22 days)
D21: Day 21; FISH: Fluorescent In Situ Hybridization; F/U: follow-up; 
N/A: Not applicable. $The currently reported case. *This patient had 
allogeneic stem cell transplantation and post-transplant FISH result 
(143 days after the initial induction chemotherapy) was negative.
Figure 2. Increase of blasts identified by flow cytometry. Twenty-one percent of total cells are blasts that are positive 
for CD34, CD117, and CD33.
immunophenotyping showed that 21% of total 
cells were blasts with partial co-expression of 
CD34, CD33, CD64 and CD117 (Figure 2). 
Based on these findings the case was called 
‘persistent AML’ and the patient received re-
induction chemotherapy with 5+3 per protocol. 
However, in the days following morphologic 
review of the bone marrow, FISH studies were 
performed and showed no evidence CBFB rear-
rangement. These latter results are most con-
sistent with increased blasts due to a recover-
ing marrow as they did not harbor the clonal 
CBFB rearrangement identified at diagnosis. 
Following induction, the patient received three 
cycle of high dose cytarabine and dasatinib 
consolidation chemotherapy followed with 
dasatinib maintenance therapy. All subsequent 
bone marrows (up to 14 months post induction) 
showed no evidence of recurrent leukemia 
by morphology and cytogenetics/FISH. 
These findings further support that the 
increased bone marrow blasts seen in the 
post induction marrow were not part of the 
AML clone. 
Marked increases of non-neoplastic 
myeloblasts in post-induction is a rare 
observation. A review of the English litera-
ture showed a single report of increased 
non-neoplastic blasts in the peripheral 
blood around Day 21 post induction [3]. 
Interestingly, this case is also an AML 
patient with CBFB rearrangement [3]. One 
possible explanation for increased non-
neoplastic blasts post-induction is that, com-
pared to the Day-14 marrows, Day 21 marrows 
have higher percentage of non-neoplastic 
blasts in AML cases with CBFB rearrange-
ments. To test this hypothesis, we collected all 
the consecutive Day 21 marrows from AML with 
CBFB rearrangements at Washington University 
in last three years. There were 7 cases in total 
with 3 male and 4 female (Table 1). Except for 
the current case (Case 1), the other 6 cases did 
not show increased blast counts and the blast 
percentage ranged from 0-4% with an average 
of 1.8%. In comparison, Day 14 marrows from 
eleven cases of AML with CBFB rearrange-
ments during the same time period had blast 
counts ranging from 0% to 4% (specifically, 5 
cases with 0%, 3 cases with 1%, 1 case with 
2%, 1 case with 3% and 1 case with 4% blasts, 
respectively). The average blast count of the 
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eleven Day 14 marrows was 1.1%. The blast 
percentages between Day 21 and Day 14 mar-
rows were not significantly different (p = 0.30). 
Even though limited by the number of available 
cases, our data argue against the hypothesis 
that in general, Day 21 bone marrows show 
higher blast counts than that of Day 14 mar-
rows in AML cases with CBFB rearrangements.
Discussion
CALGB 10801 is an on-going phase II clinical 
trial to assess the safety and tolerability of 
dasatinib with induction, consolidation and 
maintenance chemotherapy in newly diag-
nosed acute myeloid leukemia (http://www.
clinicaltrials.gov/, Identifier: NCT01238211). 
The induction therapy is one course of 7+3 
(daunorubicin, cytarabine) plus dasatinib. If 
Day 21 bone marrow shows cellularity ≥ 20% 
and leukemic blasts ≥ 5%, a re-induction thera-
py with 5+3 (cytarabine, daunorubicin) plus 
dasatinib would be given. Unfortunately, our 
patient had received the re-induction before 
FISH results were available. Consolidation ther-
apy is 4 courses of high dose cytarabine + 
dasatinib. Our patient had been treated with 
only 3 courses due to neutropenia and throm-
bocytopenia. Maintenance therapy is 12 cours-
es of dasatinib.
AML with inv(16) or t(16;16) involves CBFB and 
MYH11 genes and usually shows both mono-
cytic and granulocytic differentiation with the 
characteristic abnormal eosinophils containing 
basophilic granules. Inv(16) or t(16;16) is favor-
able translocation and the group has a com-
plete remission rate of approximately 85%, 
which is not affected by additional cytogenetic 
abnormalities [2].
Secondary cytogenetic abnormalities are 
reported in approximately 40% cases of AML 
with CBFB rearrangements, common forms 
including +22, +8, del(7q), and +21 [4]. t(11;20) 
(p15;q11.2) is a rare recurrent nonrandom 
translocation, and was reported to result in 
NUP98/TOP1 fusion protein [5]. It has been 
rarely reported in AML and other myeloid neo-
plasms. Our case is the first reported t(11;20)
(p15;q11.2) case in an AML with CBFB rear-
rangement. NUP98 (Nucleoporin 98 gene) on 
chromosome 11 is a component of nuclear 
pore complex. To date, translocations involving 
NUP98 have been reported with 28 different 
partner genes in hematologic malignancies, 
predominantly myeloid neoplasms [6]. NUP98 
was believed to have roles in transcription, and 
cell cycle regulation, and Murine models of 
NUP98 fusion proteins have shown evidence of 
leukemogenicity [6]. 
A marked increase of non-neoplastic blasts is a 
rare observation in post-induction bone mar-
row, and occurs due to an unknown mecha-
nism. Such cases could represent a diagnostic 
pitfall, if cytogenetic results are not available, 
and could result in unnecessary chemotherapy. 
If unexpectedly high blast counts are seen in a 
post-induction bone marrow biopsy from 
patients with favorable cytogenetic abnormali-
ties, such as t(8;21) and inv(16), close observa-
tion of the blast count trend and correlation 
with cytogenetic findings should be consid- 
ered. 
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